| abstract |
The invention discloses an arylformyl-substituted tricyclic compound or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof which has inhibitory effect on BTK, as shown in formula I, wherein each of the The definition of the group is detailed in the specification. In addition, the present invention also discloses a pharmaceutical composition comprising the compound, and its application in the preparation of a medicament for a disease or condition related to BTK and/or abnormal B cell activation. |